<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK555333" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK555333/" /><meta name="ncbi_pagename" content="Eteplirsen - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Eteplirsen - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Eteplirsen" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/02/27" /><meta name="citation_pmid" content="32223120" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK555333/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Eteplirsen" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/02/27" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK555333/" /><meta name="description" content="Eteplirsen is synthetic antisense oligonucleotide designed to cause skipping of abnormal exons during synthesis of the dystrophin gene and that is used to treat Duchenne muscular dystrophy. Clinical experience with eteplirsen has been limited, but it has not been linked to serum enzyme elevations or to instances of acute liver injury with symptoms and jaundice." /><meta name="og:title" content="Eteplirsen" /><meta name="og:type" content="book" /><meta name="og:description" content="Eteplirsen is synthetic antisense oligonucleotide designed to cause skipping of abnormal exons during synthesis of the dystrophin gene and that is used to treat Duchenne muscular dystrophy. Clinical experience with eteplirsen has been limited, but it has not been linked to serum enzyme elevations or to instances of acute liver injury with symptoms and jaundice." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK555333/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Eteplirsen/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK555333/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88232404680E310000000000430012.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK555333_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK555333_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Etanercept/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ethambutol/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK555333_"><span class="title" itemprop="name">Eteplirsen</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 27, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Eteplirsen.OVERVIEW"><h2 id="_Eteplirsen_OVERVIEW_">OVERVIEW</h2><div id="Eteplirsen.Introduction"><h3>Introduction</h3><p>Eteplirsen is synthetic antisense oligonucleotide designed to cause skipping of abnormal exons during synthesis of the dystrophin gene and that is used to treat Duchenne muscular dystrophy. Clinical experience with eteplirsen has been limited, but it has not been linked to serum enzyme elevations or to instances of acute liver injury with symptoms and jaundice.</p></div><div id="Eteplirsen.Background"><h3>Background</h3><p>Eteplirsen (e&#x0201d; tep lir&#x02019; sen) is a synthetic antisense oligonucleotide designed to cause exon 51 skipping in the processing of mRNA for the dystrophin gene, which encodes an essential protein for muscle integrity. Patients with Duchenne muscular dystrophy typically have deletion mutations in exons [43 to 55] of the dystrophin gene, which disrupt the open-reading frame and the normal synthesis of the protein. Without dystrophin, muscle fibers become damaged during contraction resulting in inflammation and eventually replacement of muscle by fibrous and adipose tissue. Duchenne muscular dystrophy is an X-linked recessive disease that generally becomes clinically apparent by the age of 2 or 3 years, resulting in gradual loss of muscle and progressive disability often leading to loss of ambulation by age 10, ventilatory failure in early adulthood, and death in the 20s or 30s. In cell culture, antisense molecules were designed that allowed for skipping of the abnormal exon 51 found in 10% to 12% of patients with Duchenne muscular dystrophy and that replaced the defective dystrophin gene with a truncated but functional dystrophin molecule. In animal models, eteplirsen led to increases in truncated muscle dystrophin. In small clinical trials, eteplirsen was found to increase levels of dystrophin protein in muscle, on the basis of which it was approved for use in patients with Duchenne muscular dystrophy with a confirmed mutation in the dystrophin gene amenable to exon 51 skipping. Eteplirsen is available in solution in single dose vials of 100 mg or 500 mg (50 mg/mL). The recommended regimen is 30 mg per kg body weight once weekly by intravenous infusion. Side effects of eteplirsen include headache, fever, falls, abdominal pain, cough and nausea. Injection site reactions and hypersensitivity reactions including rash, pruritus, urticaria and skin exfoliation have occurred. Because eteplirsen is infused weekly, most patients have indwelling venous access catheters placed, which may pose a risk for complications of infection and septicemia.</p></div><div id="Eteplirsen.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Duchenne muscular dystrophy is a rare disease, affecting ~1:5000 newborn boys, and those with deletion mutants in exon 51 account for only 13% of patients with the disease. Because the pivotal trials of eteplirsen were conducted in small numbers of patients, the full spectrum of adverse events and hepatotoxicity may not be fully known. Nevertheless, serum aminotransferase elevations were not described in the registration trials of eteplirsen and there were reportedly no discontinuations because of adverse events. Thus, eteplirsen has not been linked to instances of acute hepatitis or jaundice, but it has had limited clinical use.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Eteplirsen.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>How eteplirsen might cause liver injury is not known. One possibility is that exon skipping may cause disruption of translation of other genes. It is metabolized by intracellular nucleases and has little effect on cytochrome P450 enzyme activities.</p></div><div id="Eteplirsen.Outcome_and_Management"><h3>Outcome and Management</h3><p>Eteplirsen therapy has not been associated with hepatic injury, either in the form of minor serum enzyme elevations or clinically apparent liver injury. Monitoring of liver tests during therapy is not recommended.</p><p>Drug Class: Genetic Disorder Agents</p><p>Other Therapeutic siRNA and Antisense Agents: <a href="/books/n/livertox/Givosiran/">Givosiran</a>, <a href="/books/n/livertox/Golodirsen/">Golodirsen</a>, Patisiran</p></div></div><div id="Eteplirsen.PRODUCT_INFORMATION"><h2 id="_Eteplirsen_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Eteplirsen &#x02013; Exondys 51&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Genetic Disorder Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33bff678-7829-479e-9110-b8e33a0bc0aa" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Eteplirsen.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Eteplirsen_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Eteplirsen.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK555333/table/Eteplirsen.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Eteplirsen.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Eteplirsen.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Eteplirsen.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_b_Eteplirsen.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Eteplirsen.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Eteplirsen.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eteplirsen</td><td headers="hd_b_Eteplirsen.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135267507" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">1173755-55-9</a></td><td headers="hd_b_Eteplirsen.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C364-H569-N177-O122-P30</td><td headers="hd_b_Eteplirsen.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135267507" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135267507" alt="image 135267507 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Eteplirsen.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Eteplirsen_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 27 February 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Eteplirsen.REF1">Abbreviations: siRNA, small interfering RNA.</div></li><li><div class="bk_ref" id="Eteplirsen.REF.mendell.2013.637">Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, et al. Eteplirsen Study Group.  Eteplirsen for the treatment of Duchenne muscular dystrophy. <span><span class="ref-journal">Ann Neurol. </span>2013;<span class="ref-vol">74</span>(5):637–47.</span> [<a href="/pubmed/23907995" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23907995</span></a>]<div><i>(In a small randomized controlled trial, 12 boys with Duchenne muscular dystrophy and mutations in exon 51 of the dystrophin gene were treated with eteplirsen [30 or 50 mg/kg intravenously] or placebo once weekly for 24 weeks, after which the placebo recipients received eteplirsen; muscle biopsies taken before and at 24 and 48 weeks showed increases in dystrophin with treatment and there were no treatment related side effects and no change in liver chemistries).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, no cases were attributed to RNAi or antisense therapies or medications for muscular dystrophy).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.mendell.2016.257">Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, et al. Eteplirsen Study Group and Telethon Foundation DMD Italian Network.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. <span><span class="ref-journal">Ann Neurol. </span>2016;<span class="ref-vol">79</span>:257–71.</span> [<a href="/pmc/articles/PMC5064753/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5064753</span></a>] [<a href="/pubmed/26573217" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26573217</span></a>]<div><i>(Follow up study of 12 patients with Duchenne muscular dystrophy treated with eteplirsen for up to 36 months [Mendell 2013] found improvements in pulmonary function tests and 6 minute walk tests in eteplirsen treated compared to historical untreated controls; therapy was well tolerated and &#x0201c;there was no signs of symptoms of hepatic toxicity&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.summary.2016">FDA. Summary Review and Evaluation. Eteplirsen. 2016. Available at: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488_summary%20review_Redacted.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.accessdata<wbr style="display:inline-block"></wbr>​.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>​/nda/2016/206488_summary<wbr style="display:inline-block"></wbr>​%20review_Redacted.pdf</a>.<div><i>(The FDA clinical review of eteplirsen for efficacy and safety found only marginal evidence of benefit and no major safety issues, although the number of patients treated with eteplirsen that could be evaluated were few; there were no liver related serious adverse events or discontinuations and no mention of ALT elevations during therapy).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.syed.2016.1699">Syed YY. Eteplirsen: First global approval. <span><span class="ref-journal">Drugs. </span>2016;<span class="ref-vol">76</span>:1699–704.</span> [<a href="/pubmed/27807823" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27807823</span></a>]<div><i>(Review of the mechanism of action, history of development, clinical efficacy and safety of eteplirsen shortly after its approval as therapy of Duchenne muscular dystrophy in patients with confirmed mutation in exon 51 of the dystrophin gene, the approval being based upon increased dystrophin levels in muscle biopsies and not upon clinical benefit; there were no discontinuations for adverse events and &#x0201c;no clinically relevant effects&#x0201d; on liver function).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF7">Eteplirsen (Exondys 51) for Duchenne muscular dystrophy. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2016;<span class="ref-vol">58</span>(1507):145–6.</span> [<a href="/pubmed/27805575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27805575</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety and costs of eteplirsen shortly after its approval in the US as therapy of Duchenne muscular dystrophy mentions that there was no evidence of clinical benefit of therapy and that the minimal increases in dystrophin levels in muscle were of uncertain clinical relevance; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.kesselheim.2016.2357">Kesselheim AS, Avorn J. Approving a problematic muscular dystrophy drug: implications for FDA policy. <span><span class="ref-journal">JAMA. </span>2016;<span class="ref-vol">316</span>:2357–8.</span> [<a href="/pubmed/27775756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27775756</span></a>]<div><i>(Commentary on the approval of eteplirsen by the FDA pointing out the lack of rigor in the clinical studies on its effects and the use of a surrogate marker to assess efficacy that has never been shown to reflect or predict clinical improvement).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.chi.2017.823">Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics. <span><span class="ref-journal">Drug Discov Today. </span>2017;<span class="ref-vol">22</span>:823–33.</span> [<a href="/pubmed/28159625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28159625</span></a>]<div><i>(Oligonucleotide and siRNA based treatments are currently being evaluated in several diseases and have been found to have unexpected toxicities including antisense thrombocytopenia [mipomersen, drisapersen] and peripheral neuropathy [revusiran]; no discussion of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.messina.2018.1837">Messina S, Vita GL. Clinical management of Duchenne muscular dystrophy: the state of the art. <span><span class="ref-journal">Neurol Sci. </span>2018;<span class="ref-vol">39</span>:1837–45.</span> [<a href="/pubmed/30218397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30218397</span></a>]<div><i>(Review of current optimal clinical management of Duchenne muscular dystrophy focusing upon standard respiratory, cardiovascular, orthopedic and nutritional support as well as recent innovative approaches to therapy including exon skipping and premature stop codon suppression).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.aartsmarus.2018.454">Aartsma-Rus A, Arechavala-Gomeza V. Why dystrophin quantification is key in the eteplirsen saga. <span><span class="ref-journal">Nat Rev Neurol. </span>2018;<span class="ref-vol">14</span>:454–6.</span> [<a href="/pubmed/29967362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29967362</span></a>]<div><i>(Editorial discussing eteplirsen which was approved based upon its effects in increasing dystrophin levels in muscle rather than a clinical effect on preventing progression of disease mentions the challenges of accurate measurement of dystrophin levels and the limited amount of uncontrolled clinical data on the effects of eteplirsen therapy on ambulation and muscle strength).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.charleston.2018.e2146">Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, Young GD, et al.  Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production. <span><span class="ref-journal">Neurology. </span>2018;<span class="ref-vol">90</span>:e2146–e2154.</span> [<a href="/pubmed/29752304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29752304</span></a>]<div><i>(Reanalysis of the muscle biopsies from the initial trial of eteplirsen in 12 patients with Duchenne muscular dystrophy found increased levels of dystrophin after 24, 48 and 180 weeks of treatment by RT-PCR, Western blot, immunohistochemistry and immune fluorescence using untreated controls to estimate baseline levels of the protein).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.verhaart.2019.373">Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. <span><span class="ref-journal">Nat Rev Neurol. </span>2019;<span class="ref-vol">15</span>:373–86.</span> [<a href="/pubmed/31147635" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31147635</span></a>]<div><i>(Review of the pathogenesis, clinical features and natural history of Duchenne muscular dystrophy and recent innovative approaches to treating the underlying genetic defect; this X-linked recessive disorder affects approximately 1 in 5000 boys and is associated with progressive loss of muscle function, presenting clinically by 2-3 years of age and leading to disability in childhood with loss of ambulation by age 12, ventilatory failure by age 20 and death during the 3rd or 4th decade of life; innovative approaches include exon skipping, genome editing, stop codon readthrough, stem cell therapy, and amelioration of secondary pathology with antiinflammatory agents and antioxidants).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.alfano.2019.e15858">Alfano LN, Charleston JS, Connolly AM, Cripe L, Donoghue C, Dracker R, Dworzak J, et al.  Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. <span><span class="ref-journal">Medicine (Baltimore). </span>2019;<span class="ref-vol">98</span>:e15858. </span> [<a href="/pmc/articles/PMC6617421/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6617421</span></a>] [<a href="/pubmed/31261494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31261494</span></a>]<div><i>(Detailed description of 2 of the initial 12 patients receiving eteplirsen for Duchenne muscular dystrophy who had rapid loss of ambulation but were continued on treatment and who remained relatively stable thereafter; in long term follow up there were no serious hepatic adverse events and no mention of ALT elevations in the listing of side effects).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.khan.2019.213">Khan N, Eliopoulos H, Han L, Kinane TB, Lowes LP, Mendell JR, Gordish-Dressman H, et al. Eteplirsen Investigators and the CINRG DNHS Investigators.  Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. <span><span class="ref-journal">J Neuromuscul Dis. </span>2019;<span class="ref-vol">6</span>:213–25.</span> [<a href="/pmc/articles/PMC6598025/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6598025</span></a>] [<a href="/pubmed/30856119" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30856119</span></a>]<div><i>(Among 74 patients with Duchenne muscular dystrophy treated with eteplirsen and corticosteroids in 3 prospective trials, the average yearly decline in forced vital capacity was less [-2.2% to -3.8%] than in a matched, untreated control group [-6.0%]).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.levin.2019.57">Levin AA. Treating disease at the RNA level with oligonucleotides. <span><span class="ref-journal">N Engl J Med. </span>2019;<span class="ref-vol">380</span>:57–70.</span> [<a href="/pubmed/30601736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30601736</span></a>]<div><i>(Review of the mechanism of action, current status and future promise of RNA based therapies that use synthetic oligonucleotides to modulate RNA function and have been applied to diseases ranging from hemophilia, amyloidosis, muscular dystrophy and hyperlipidemia).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.aartsmarus.2019.13">Aartsma-Rus A, Goemans N. A sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe. <span><span class="ref-journal">Nucleic Acid Ther. </span>2019;<span class="ref-vol">29</span>:13–5.</span> [<a href="/pubmed/30526286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30526286</span></a>]<div><i>(Editorial discussing eteplirsen which was approved for use in Duchenne muscular dystrophy in the US but not in Europe, while atauren, another mutation specific therapy, was approved in the US but not in Europe).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.setten.2019.421">Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2019;<span class="ref-vol">18</span>:421–6.</span> [<a href="/pubmed/30846871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30846871</span></a>]<div><i>(Extensive review of gene silencing using RNA interference pathways and the potential of RNAi therapeutics which has promise in many genetic and acquired diseases including transthyretin amyloidosis [transthyretin], HIV infection [CCR5], HBV [HBV mRNA], alpha-1-antitrypsin deficiency [zz A1AT], hypercholesterolemia [PCSK9]).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.verhaart.2019.373_1">Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. <span><span class="ref-journal">Nat Rev Neurol. </span>2019;<span class="ref-vol">15</span>:373–6.</span> [<a href="/pubmed/31147635" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31147635</span></a>]<div><i>(Review of mechanisms, challenges, and clinical efficacy of new molecular approaches to therapy of muscular dystrophy including gene therapy with viral vectors, exon skipping using antisense oligonucleotides [casimersen, eteplirsen, drisapersen, golodirsen], stop coding readthrough [ataluren], gene addition, CRISPR-Cas9 genome editing, and myoblast transplantation).</i></div></div></li><li><div class="bk_ref" id="Eteplirsen.REF.aartsmarus.2020">Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy. <span><span class="ref-journal">Nucleic Acid Ther. </span>2020 Feb 11;</span> [Epub ahead of print] [<a href="/pmc/articles/PMC7133412/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7133412</span></a>] [<a href="/pubmed/32043902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32043902</span></a>]<div><i>(Review of the efficacy and safety of 10 oligonucleotide therapies approved in the US or Europe, including specific discussions of formvirsen, mipomersen, eteplirsen, nusinersen, patisiran, givosiran and golodirsen).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK555333</span><span class="label">PMID: <a href="/pubmed/32223120" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">32223120</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Etanercept/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ethambutol/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK555333&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK555333/?report=reader">PubReader</a></li><li><a href="/books/NBK555333/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK555333" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK555333" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Eteplirsen. [Updated 2020 Feb 27].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK555333/pdf/Bookshelf_NBK555333.pdf">PDF version of this page</a> (102K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Eteplirsen/AE)%20AND%20Human%5bMH%5d%20AND%20(drug%20induced%20liver%20injury%20OR%20jaundice/CI%20OR%20bile%20duct%20diseases/CI%20OR%20liver/DE%20OR%20liver%20diseases/CI)%20AND%20(%221900%5C%5C1%5C%5C1%22%5bEDat%5d:%222999%5C%5C12%5C%5C31%22%5bEDat%5d)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Eteplirsen: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Eteplirsen" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Eteplirsen: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4953708" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4953708" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4953708" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/32223119" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Golodirsen</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Golodirsen<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28865998" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.</a><span class="source">[Mol Ther. 2017]</span><div class="brieflinkpop offscreen_noflow">Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Ther. 2017 Nov 1; 25(11):2561-2572. Epub 2017 Jul 28.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29067661" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Designing Effective Antisense Oligonucleotides for Exon Skipping.</a><span class="source">[Methods Mol Biol. 2018]</span><div class="brieflinkpop offscreen_noflow">Designing Effective Antisense Oligonucleotides for Exon Skipping.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shimo T, Maruyama R, Yokota T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Methods Mol Biol. 2018; 1687:143-155. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29752304" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.</a><span class="source">[Neurology. 2018]</span><div class="brieflinkpop offscreen_noflow">Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, Young GD, Milici AJ, Voss J, DeAlwis U, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurology. 2018 Jun 12; 90(24):e2146-e2154. Epub 2018 May 11.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28280301" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Eteplirsen in the treatment of Duchenne muscular dystrophy.</a><span class="source">[Drug Des Devel Ther. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Eteplirsen in the treatment of Duchenne muscular dystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lim KR, Maruyama R, Yokota T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drug Des Devel Ther. 2017; 11:533-545. Epub 2017 Feb 28.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=32223120" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=32223120" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468212ddcb804c59e3204c">Eteplirsen - LiverTox</a><div class="ralinkpop offscreen_noflow">Eteplirsen - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:59:14-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE88232404680E310000000000430012&amp;ncbi_session=CE88232404682111_0067SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK555333%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK555333&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK555333/&amp;ncbi_pagename=Eteplirsen - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88232404682111_0067SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>